针对渐进性多发性硬化症中的衰老微质:一种基于老年科学的方法
Jeffrey Atkinson1,2, Amy Dokiburra2, Hayley Groover2,3
1Department of Neurology, The Ohio State University College of Medicine, Wexner Medical Center, Columbus, OH, United States.
Frontiers in immunology
|October 23, 2025
概括
细胞衰老通过促进炎症和神经退行导致渐进的多发性硬化症 (MS). 针对衰老细胞的老化疗法在减少多发性硬化症的严重程度和改善结果方面表现有前途.
科学领域:
- 神经免疫学 神经免疫学
- 地质科学是地球科学.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 多发性硬化症 (MS) 是一种中枢神经系统疾病,其特征是神经炎症和神经退行,随着年龄的增长,疾病的严重程度会增加.
- 细胞衰老,标志着一种亲炎症衰老相关的分泌表型 (SASP),加剧组织损伤,并与MS的发病有关.
- 多发性硬化病变内的衰老的微质细胞可能会损害复髓化并恶化神经退行,从而产生有害的循环.
研究的目的:
- 在MS的小鼠模型中研究老化剂的治疗潜力.
- 为了确定是否准细胞衰老可以改善疾病进展和改善实验性自身免疫脑膜炎 (EAE) 的结果.
主要方法:
- 在中年老鼠中利用实验性自身免疫脑膜炎 (EAE),一种MS的模型.
- 给EAE小鼠使用的老化药物达沙替尼加奎尔 (D+Q) 或纳维托克拉克斯.
- 评估了临床结果,生存率和衰老细胞负担.
主要成果:
- 用D+Q或纳维托克拉克斯治疗中年EAE小鼠显著改善了临床结果和生存率.
- 治疗减少了中枢神经系统 (CNS) 中衰老的微质的负担.
- 结果表明,EAE严重程度的衰减与年龄和药物相关.
结论:
- 老化疗法是一种有前途的基于老年科学的战略,用于进展性多发性硬化.
- 针对细胞衰老可能为神经炎症和神经退行性疾病提供一种新的治疗方法.
- 需要进一步的研究来将老化疗法转化为人类MS临床应用.
相关概念视频
01:26Aging
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...